Stock Price

(NASDAQ: INSM)

Price:
20.16

Change:
- 0.17

Day High:
21.15

Day Low:
19.69

Volume:
759,200

4:00 PM ET on
Mar 6, 2015
Delayed ~20 min. By eSignal.

Overview

We are focused on developing and commercializing drugs that treat very serious lung infections in orphan disease populations.


Investment Thesis

Our lead product candidate, ARIKAYCE, is being developed for patients with severe lung infections.

  • ARIKAYCE is a proprietary inhaled liposomal formulation of the antibiotic amikacin, currently administered intravenously for a range of infections
  • The product is delivered through a specialized nebulizer engineered to deliver amikacin directly to the site of serious lung infections
  • ARIKAYCE is designed for once daily administration

We have multiple near‐term commercial opportunities in orphan lung diseases.

  • In 2014, Insmed filed a Marketing Authorization Application (MAA) with the EMA for ARIKAYCE for the treatment of NTM lung infections as well as Pseudomonas aeruginosa lung infections in cystic fibrosis patients.
  • Insmed is proceeding with a phase 3 study in patients with NTM lung infection. We anticipate having preliminary top-line clinical results from the confirmatory phase 3 study in 2016.

 We have a solid and broad IP portfolio.

  • More than a decade of investment in research and development
  • Potential coverage into 2029

 We are well-capitalized and are building out our infrastructure.

  • $167.3 million in cash (as of September 30, 2014)

View all »   RSSNews Releases

Feb 27, 2015
Insmed Reports 2014 Fourth Quarter and Full Year Financial Results

Feb 24, 2015
Insmed to Participate at Cowen & Company's 35th Annual Health Care Conference

View all »Events

Mar 3, 2015
Insmed to Participate at Cowen & Company's 35th Annual Health Care Conference
Webcast Listen to webcast

Feb 11, 2015
2015 Leerink Global Healthcare Conference
Webcast Listen to webcast

Investor Materials

View the latest Insmed Investor Presentation here.

Learn More

Key Clinical Publications

Insmed actively publishes and presents clinical data for its product candidates.

Learn More

Email Alerts

Want to stay up to date on our news, events, and filings?

Set up your email alerts. Learn More

Investor & Media Contacts

Investor Relations
Anne Marie Fields
Senior Vice President
LHA
Phone: (212) 838-3777
E-mail

Bruce Voss
Managing Director
LHA
Phone: (310) 691-7100
E-mail

loading